| 2023 | ➢FHB and Far Eastern Memorial Hospital announced an IND protocol “the Phase I/IIa Clinical Trial of Autologous Epstein-Barr virus-specific cytotoxic T cell-based Immunotherapy for Patients with Nasopharyngeal Carcinoma” was approved by Taiwan Food and Drug Administration (TFDA) of Ministry of Health and Welfare (MOHW). ➢FHB and Kaohsiung Medical University Chung-Ho Memorial Hospital cooperated the pre-clinical trial of Establishment of a novel manufacturing process for EBV-specific cytotoxic T cells from EBV-associated malignancies. ➢FHB and National Cheng Kung University Hospital cooperated the pre-clinical trial of circulating tumor cells and immune cells difference between the healthy and the cancer ones. ➢FHB and Kaohsiung Medical University Chung-Ho Memorial Hospital cooperated the pre-clinical trial of circulating tumor cells and immune cells difference between the healthy and the cancer ones. |
| 2022 | ➢FHB and Far Eastern Memorial Hospital were awarded The 19th National Innovation Award in the Academic Research Category by「Artificial Intelligence-based Immune Monitoring and Personalized Immune Cell Therapy for Nasopharyngeal Carcinoma」. ➢FHB and Far Eastern Memorial Hospital cooperated the pre-clinical trial of Adipose-derived stem cell（ADSC）. ➢FHB and Taipei Veterans General Hospital cooperated the pre-clinical trial of circulating tumor cells and immune cells difference between the healthy and the cancer ones. ➢FHB was authorized the Mycoplasma test of LDTS by the Food and Drug Administration of Taiwan (TFDA). ➢MOHW approved the cell therapy project of CIK cells which cooperates with Kaohsiung Medical University Chung-Ho Memorial Hospital. |
| 2021 | ➢FHB was awarded the Symbol of National Quality (SNQ) for Precision Diagnosis and Personalized Medicine of Immunotherapy in Dec., 2021. ➢FHB announced to cooperate with Far Eastern Memorial Hospital in the clinical trial of Epstein-Barr virus-specific cytotoxic T cells (EBaT8) targeting patients with nasopharyngeal carcinoma. ➢FHB and Department of Obstetrics & Gynecology of National Taiwan University Hospital cooperated the pre-clinical trial of circulating tumor cells and immune cells difference between the healthy and the cancer ones. ➢FHB and Kaohsiung Medical University Chung-Ho Memorial Hospital cooperated the pre-clinical trial of Innovative study of novel TCR Gamma-delta T cell identification and manufacturing process development. ➢FHB and Rheumatology Taipei Veterans General Hospital cooperated the pre-clinical trial of Study of a regulatory role of novel FHCT002 in autoimmune disease. |
| 2020 | ➢FHB was approved for IND of PHYDUXON in combination with atezolizumab on phase I / IIa by FDA in Dec., 2020. ➢FHB was issued the excelsior award in recognition of continuing innovations and advancements in R&D in Dec., 2020. ➢FHB and Far Eastern Memorial Hospital cooperated the pre-clinical trial of circulating tumor cells and immune cells difference between the healthy and the cancer ones in Jul., 2020. ➢FHB obtained the patent of modified natural killer T cells, pharmaceutical compositions and uses thereof from Taiwan, China and U.S.A. in Jun., Oct. and Dec., 2020. ➢FHB and Taipei Veterans General Hospital applied cytokine-induced killer (CIK) cell therapy on liver cancer, lung cancer, etc., in Apr., 2020. |
| 2019 | ➢ FHB was awarded the Symbol of National Quality (SNQ) for Precision Diagnosis and Personalized Medicine of Immunotherapy in Dec., 2019. ➢ FHB was authorized with non-exclusive license from Academia Sinica in May, 2019. ➢ The contributed capital was NT 221,000,000. ➢ FHB gained investment from National Development Fund in Apr., 2019. |
| 2018 | ➢ FHB applied a clinical trial of FHCT003 on phase I / II a by FDA in Oct., 2018. ➢ FHB was proved on phase I clinical trials by TFDA in Mar., 2018. |
| 2017 | ➢ FHB was awarded the 14th National Innovation Award for Comprehensive Profiling of the Human Immune System for Clinical Drug Development and Individual Disease Risk Assessment in the Innovative Service Category by the Institute for Biotechnology and Medicine Industry in Dec., 2017. ➢ The contributed capital was NT 201,000,000. ➢ FHB was the first bio-company in Taiwan accredited certificate of foreign cell processor by Pharmaceuticals and Medical Devices Agency (PMDA) in Japan in Feb., 2017. ➢ FHB achieved pharmacist manufacturing license. |
| 2016 | ➢ FHB was issued with ISO/IEC 17025 testing laboratory certification from Taiwan Accreditation Foundation (TAF) in Feb., 2016. ➢ The contributed capital was NT 181,000,000. |
| 2015 | ➢ The contributed capital was NT 146,000,000. ➢ FHB's GTP laboratory acquired verification and started operation. ➢ FHB achieved pharmacist selling license. |
| 2014 | ➢ The contributed capital was NT 135,000,000. ➢ FHB was permitted to undergo the immune cell therapy of FHCT001 on phase I clinical trial in Taipei Veterans General Hospital. |
| 2013 | ➢ The clinical trial application of FHB was issued with important index by CDE. ➢ FHB applied the immune cell therapy of FHCT001 on phase I clinical trial to TFDA. ➢ FHB was summited for IND approval on phase I by TFDA in Jul., 2013. ➢ FHB signed up the cooperation with Taipei Veterans General Hospital. ➢ The contributed capital was NT 59,000,000. |
| 2012 | ➢ FHB founded. The contributed capital was NT 10,000,000. |
